Ultromics Raises $55M in Series C
Ultromics has successfully raised $55M in a Series C at a $300M valuation led by Optum Ventures, Oxford Science Enterprises.
Company Overview
Ultromics is a HealthTech company headquartered in Oxford, UK, founded in 2017 with 120+ employees.
AI for cardiac imaging
Fundraising Details
- Amount Raised: $55M
- Round Type: Series C
- Valuation: $300M
- Date: 2025-01-01
- Investors: Optum Ventures, Oxford Science Enterprises
About Ultromics
AI for cardiac imaging The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Oxford, UK
- Founded: 2017
- Team Size: 120+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Ultromics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Ultromics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $300M valuation marks an important milestone for Ultromics, positioning the company among notable players in the HealthTech industry.
Looking Ahead
With this new capital, Ultromics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-01-01. For more information about Ultromics, visit their headquarters at Oxford, UK.
